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Background: There are many therapeutic methods for allergic conditions. CpG oli-
gonucleotides play a critical role in immunity via the augmentation of Th1 and suppres-
sion of Th2 responses. Objective: In the present study we aimed to estimate the effec-
tiveness of intranasal administration of CpG ODN plus Chenopodium album allergen in 
allergic asthma compared with the administration of allergen alone and to find out how 
CpG ODN therapy is useful in the treatment of allergen induced asthma. Methods: 
BALB/c Mice were intraperitoneally and intranasally sensitized with allergenic extract 
precipitated on aluminum hydroxide. Therapy with CpG/Ag was performed intrana-
sally. After antigenic challenge, a number of Immunologic variables such as serum IgE 
and IgG, systemic and local IL-10 and IFN-γ were studied in splenocytes, and lung tis-
sue culture supernatants, respectively. Results: Our study indicated that intranasal ad-
ministration of CpG/Ag had significant increases in both systemic and local levels of 
IL-10 and IFN-γ (p≤ 0.001), but showed no significant effect on the levels of IgE, 
IgG2a, and IgG1 in serum (p= 0.06). This study demonstrated that CpG ODN has thera-
peutic effects not only on splenocytes but also on nasal lymphocytes to produce IFN-γ 
as a Th1 cytokine, and IL-10 as a regulatory cytokine. Conclusion: According to these 
data from the mouse model, we conclude that intranasal administration of CpG motifs 
before allergen exposure may be useful for the control of allergic asthma. Therefore, 
further investigations on humans using CpG motifs are recommended in order to modu-
late the allergic effects of Chenopodium album as well as other regional allergens. 
 





Inhalation of allergens in susceptible subjects evokes immune and inflammatory responses  
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in the airway, resulting in bronchial asthma (1). Allergic diseases are candidate for immuno-
therapy, due to their nature in which antigen-specific Th2 cells induce most allergic mani-
festations (2). CpG motifs recognized via Toll like receptor-9 (TLR-9) are frequently found 
in bacteria (3-5). Synthetic Oligodeoxynucleotids containing CpG motifs (CpG ODNs) 
mimic the activity of bacterial DNA and have been used to explore the nature of CpG mo-
tifs (6). For the use of CpG motifs as adjuvants in the antigen-specific Th1 responses, CpG 
ODNs are often co- administered with the antigen (7). Moreover, it has been shown that 
CPG administration in previously sensitized subjects can reverse inflammatory responses 
(8). 
In the present study, we report the experimental application of CpG ODNs for the treat-
ment of bronchial asthma induced by Chenopodium album (Ch.a.), a very common aller-
genic plant in Iran. Induction of experimental asthma using Ch.a. allergen was priviously 
reported from our laboratory (9). Anti-inflammatory activity of CpG motifs is accompa-
nied by the improvement of airway hyperresponsiveness and the induction of IFN-γ sug-
gesting the possibility of Th1 and T regulatory involvment (10, 11). Based on these find-
ings, we used a mixture of Ch.a. allergen and CpG motifs in order to study its effective-
ness in comparison to Ag specific immunotherapy. Indeed, we hypothesised that CpG 
ODN immunotherapy may induce regulatory and Th1 responses in Ch.a. induced asthma 
in mice. There are many reports from other countries investigating different allergens. For 
example, human clinical trials on ragweed allergic rhinitis using CpG ODNs conjugated 
to the principal allergenic moiety of ragweed (Amb a 1) are carried out in the United 
States (12-14). Furthermore, based on other reports (8, 15), mucosal administration of al-
lergen in immunotherapy has a number of potential advantages over traditional intrader-
mal administration and may be the key to successful implementation of immunotherapy. 
Besides eliminating the need for injections (an important determinant of compliance, es-
pecially in children), mucosal administration has lower costs and may reduce the risk of 
anaphylactic responses. In addition, studies on CpG ODN as an immunostimulatory adju-
vant have shown that it confers more effective immune responses when administered mu-
cosally rather than parenterally (8, 13). Therefore, in this study we select the mucosal 
route of administration as an effective means of Ch.a./Ag delivery and compare its poten-
tial with Ag specific immunotherapy in sensitized mice and sham controls as well. 
 
 
MATERIALS AND METHODS 
 
CpG ODNs. The ODNs were obtained from InvivoGen, US. The CpG ODN (1826) 
consisted of 20 bases containing two CpG motifs (TCCATGACGTTCCTGACGTT). 
ODNs were in Phosphorothioate form synthesized and purified by the company using 
HPLC. 
Antigen allergenic extract was prepared from Ch.a. pollen according to previously re-
ported procedures (16). 
Animals and Experimental Design. Fifteen female BALB/c mice at 4 to 6 weeks of 
age were obtained from Pasture Institute (Tehran, Iran) and were randomly divided to 
three groups of test and two control groups, each consisting of 5 animals. Immunization 
was carried out according to our previous study (9). Briefly, all animals with the excep-
tion of the sham controls were sensitized intraperitoneally with 50 µg of Ch.a. extract pre-
cipitated with 4 mg of aluminum hydroxide (alum) in 200 µl of phosphate-buffered sa-
line (PBS) on days 1 and 7; followed by two times allergen exposure using 2% Ag solu-
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tion in PBS on days 14 and 16. All initially sensitized mice received three times immu-
notherapy on days 19, 26, and 33. Mucosal immunotherapy consisted of trans-nasal ad-
ministration of 10 µg CpG ODN  with Ch.a. (50 µg) in test group, antigen alone (50 µg 
in PBS) in antigen control mice, and PBS in sham controls.  Later, all of the mice in the 
three groups underwent repeated allergen exposure to Ch.a. allergen (2% solution  in 
PBS for  30 min) on days 40 and 47. Blood samples were obtained from all of the mice 
two days after the final antigen challenge; sera were separated and stored at -20 °C for 
antibody detection. Spleens and lungs were excised after animal sacrifice. Single-cell 
suspensions were prepared from the spleens. Lung tissues were cut to small sections (1 
mm3).  Lung sections and splenocytes were cultured in separate micro plates and culture 
supernatants were then collected and stored at -80 °C for cytokine assays. 
Cell Culture Condition. Splenocytes were plated in 24-well dishes using 5 x 106 cells 
per ml in RPMI-1640 complete medium with 10% (vol/vol) FCS, 50 mM 2-
mercaptoethanol, 100 units/ml penicillin G/streptomycin. Lung tissues were also cul-
tured in 24-well micro plates under the same conditions.  All culture reagents were pur-
chased from Sigma (US). The cells and tissues were then stimulated with 50 µg of al-
lergen and incubated at 37°C for 72 hours in a 5% CO2 atmosphere. Following 72 hours 
incubation, supernatants were harvested and stored at -80º C for cytokine analysis. The 
experiments were performed in triplicate, twice. 
Antibody Assay. ELISA assay was used to detect specific IgG antibodies and total IgE. 
All reagents were purchased from Sigma, US and Becton Dickinson, Oxnard, CA and 
experiments were carried out according to manufacturer’s instructions  
Cytokine Assay. IL-10 and IFN-γ concentrations in splenocytes and lung tissue culture 
supernatants were determined using ELISA (PharMingen San Diego, CA) method.  As-
say was performed according to the manufacturer's recommendations. The detection 
limits for IFN-γ and IL-10 were 78 pg/ml for and 19 pg/ml respectively. 
Statistical Analysis. Data were expressed as mean ± standard error of the mean. For in 
vivo experiments, each group consisted of four or five mice. Each experiment was re-





Results of IL-10 and IFN-γ assays in splenocytes and lung tissue culture supernatants are 
presented in Figure 1 and 2, respectively. Following exposure to the allergen, CpG/Ag 
treated mice induced significantly higher levels of systemic IL-10 and IFN-γ compared to 
untreated mice in sham controls and specific Ag treated mice in the positive group (p≤ 
0.001). However, these effects were not shown in the absence of CpG motifs, as observed 
in Ag-treated mice which failed to induce significant changes in systemic IL-10 (p=0.06). 
Furthermore, there was no significant rise in local IFN-γ levels of test versus Ag treated 
group (p=0.06), but IL-10 induced in the lung tissue culture of CpG/Ag treated mice was 
significantly higher than those of the two control groups (p≤ 0.001). 
The results of total serum IgE concentration and specific IgG subclasses are shown in 
Figure 3. The ratio of the OD values of IgG2a to IgG1 has been reported to demonstrate 
the shift of IgG subclass from IgG1 to IgG2a. The data in this study indicates that the 
differences in antibody concentrations between CpG/Ag, Ag alone treated and the un-
treated mice were not statistically significant (p=0.06) (Figure 4). 
 
















Figure 1. IFN-γ and IL-10 concentrations in splenocytes culture supernatants measured by 
ELISA. Sensitized test mice, sham and Ag control groups received CpG/Ch.a., PBS and Ch.a. 




Figure 2. IFN-γ and IL-10 concentrations in lung tissue culture supernatants are measured by 
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Figure 3. Total serum IgE concentrations are measured by ElISA in sensitized test mice, sham 
and Ag control groups receiving CpG/Ch.a., PBS, and Ch.a. alone, respectively. No significant 
changes are shown in test mice compared to either control groups (p=0.06). Similarly, there 

























Figure 4. Serum IgG2a and IgG1 assayed by ElISA and presented as OD ratios. Sensitized test 
mice, sham and Ag control groups received CpG/Ag, PBS, and Ch.a. alone, respectively. No 





In this study, we compared the antiallergic effects of the mucosal co-administration of 
CpG/Ch.a. with Ag immunotherapy in a mouse model of asthma. Based on the experi-
 

















ments, we detected IFN-γ induction as a marker for Th1 activity and IL-10 increase as a 
marker for regulatory responses. However, we noticed that CpG ODN effect on IL-10 
was more than its effect on IFN-γ. CpG ODN enhanced both the systemic and the local 
increase in IL-10 whereas IFN-γ was only increased systemically in response to CpG 
therapy. In order to elevate the effects of cytokines on antibody production, we meas-
ured total IgE and specific IgG subclasses as markers of allergy. In contrast to some 
other reports (17, 18), we detected no significant reduction in IgE and IgG1 levels in 
CpG treated mice compared with controls. We suggest that this failure could be attrib-
uted to short and insufficient period of time between the immunotherapy and blood 
sampling. However, the lack of reduction of IgE is not surprising as it was previously 
shown by Mo on an animal model of allergic rhinitis (19), and by Inoue on atopic derma-
titis (20). Suzuki (21) suggests that mucosal immunotherapy seems to be a successful al-
ternative to the traditional systemic routes. In our study, we found that during intranasal 
administration addition of CpG motifs to antigen makes it more potent than using Ag 
alone regarding cytokine deviations from Th2 to Th1 and regulatory like responses. In-
deed, mucosal administration of CpG ODN is able to raise the local production of IL-10 
in the lung; while this effect was not seen in local concentrations of IFN-γ. Accordingly, 
since T-reg like responses seem to be effective in immunomodulation of allergic manifes-
tations, we suggest that IL-10 induction in mice receiving CpG/Ch.a. intranasally could be 
an important factor in suppression of inflammatory responses. However, in addition to 
cytokines, further studies are required on clinical symptoms to confirm this suggestion. 
In contrast to Vipul who found that levels of IL-10 in the airways were suppressed in 
CpG-treated vs. untreated mice (15), we found a significant increase in systemic a
local production of IL-10 after CpG/Ch.a. therapy compared to the controls. Therefore, 
we suppose that a possible mechanism for the effects of CpG ODN is regulation of IL-
10. Although IL-10 is described as a Th2 cytokine (22), its role in atopic asthma is com-
plicated. In addition to its local effects on airways, IL-10 has been reported to have the 
systemic anti-inflammatory properties, suppressing both Th1 and Th2 cytokine re-
sponses, and induction of anergy or tolerance when applied to CD4+ T lymphocytes or 
dendritic cells (23, 24). In this study we have demonstrated that CpG ODNs strongly 
induce IL-10 from splenocytes and lung immune cells. We suggest that enhancement of 
IL-10 may partially mediate the protection induced by CpG ODNs against Ch.a. allergy. 
One possibility for the source of IL-10 is the regulatory T cells (CD25+CD4+, T-reg 
cells), which seem to play an important role in maintaining immunological tolerance 
(25, 26). Induction of T-reg cells might explain the antigen-specific effects of CpG 
ODNs in atopic inflammation. Thus, depending on systemic and mucosal expression, 
IL-10 can lead to beneficial consequences in asthma. Because of many advantages for 
nasal immunotherapy, such as low risk of shock and also convenience, we recommend 
to perform more investigations on CpG applications in human asthma. Based on the re-
sults obtained on Ch.a., we suggest that the administration of CpG motifs with different 
allergens can increase the therapeutic effects of allergens in specific immunotherapy.   
In conclusion, we suggest that mucosal co-administration of CpG ODNs with Ch.a. al-
lergen may reverse airway inflammation through the induction of Th1 and regulator
cytokines. Our results support the need for more studies on application of CpG ODN in 
the immunotherapy of asthma induced by Ch.a. in humans. Moreover, based on the CpG 
ODN potentials to increase the effectiveness of Ch.a., specific immunotherapy, we con-
clude that these finding could be applied for other allergens as well.  
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